InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
10
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Lyons Gary A, Director. Director active across 4 companies, notably Travere Therapeutics, Inc.. Cumulatively, 33 reports have been published. Split: 0 buy · 10 sells. Total volume traded: €3.8m. Activity tracked since 14 May 2021. The latest transaction was disclosed on 18 August 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Lyons Gary A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations33 total
2,600 shares@ US$63.49990.0028% mcap9.7% of flowCommon StockSEC:0001123343-26-000010:2
5,000 shares@ US$17.440.0015% mcap5.1% of flowCommon StockSEC:0001123343-26-000010:0
1,900 shares@ US$62.52890.0020% mcap7.0% of flowCommon StockSEC:0001123343-26-000010:1
500 shares@ US$64.1620.0005% mcap1.9% of flowCommon StockSEC:0001123343-26-000010:3
5,000 shares@ US$17.440.0015% mcap5.1% of flowCommon StockSEC:0001123343-26-000010:4
4,100 shares@ US$63.26590.0044% mcap15.3% of flowCommon StockSEC:0001123343-26-000010:5
900 shares@ US$63.85570.0010% mcap3.4% of flowCommon StockSEC:0001123343-26-000010:6
8,000 shares@ US$16.330.0023% mcap14.4% of flowCommon StockSEC:0001123343-26-000002:0
8,000 shares@ US$41.070.0059% mcap36.2% of flowCommon StockSEC:0001123343-26-000002:1
15,000 shares@ US$47.8912.2% of flowCommon StockSEC:0001123343-25-000006:0
1,435 shares0Common StockSEC:0000914475-25-000127:0
6,500 shares0Common StockSEC:0001415889-25-013499:0
40,000 shares@ US$10.48100.0% of flowCommon StockSEC:0001415889-24-024795:0
11,570 shares@ US$42.767.8% of flowCommon StockSEC:0000914475-24-000195:0
930 shares@ US$42.760.6% of flowCommon StockSEC:0000914475-24-000172:0
2,100 shares0Common StockSEC:0000914475-24-000129:0
12,500 shares@ US$42.768.6% of flowCommon StockSEC:0000914475-24-000123:0
6,500 shares0Common StockSEC:0001415889-24-012847:0
10,000 shares@ US$130.044320.6% of flowCommon StockSEC:0001209191-23-059771:0
5,000 shares@ US$12.981.0% of flowCommon StockSEC:0000914475-23-000080:0
5,000 shares@ US$12.981.1% of flowCommon StockSEC:0001209191-23-049448:0
5,000 shares@ US$12.981.0% of flowCommon StockSEC:0001209191-23-048383:0
25,000 shares0Common StockSEC:0001140361-23-034287:0
4,500 shares0Common StockSEC:0001209191-23-030959:0
15,000 shares@ US$12.713.3% of flowCommon StockSEC:0001209191-22-055393:0
25 of 33 declarations
About Lyons Gary A
Gary A. Lyons is a Director at Neurocrine Biosciences INC, Travere Therapeutics, Inc., and RIGEL PHARMACEUTICALS INC. He has 26 filings in total, and across the sampled 26 filings dated from 2021-05-18 to 2026-04-16, reported sell volume is EUR 3,291,779, with Option exercise as the most common transaction type.
